GLP-1R (30mg)
$355.00
GLP-1R 30mg – Triple GIP/GLP-1/Glucagon receptor agonist for advanced metabolic research | Research Use Only – Not for Human Consumption
GLP-1R Research Peptide
Research Use Only – Not for Human or Animal Consumption
GLP-1R is an advanced synthetic peptide characterized as a triple agonist of glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.1 This research compound represents a novel approach to investigating multi-incretin metabolic regulation, combining three distinct receptor activation pathways. GLP-1R has been studied in preclinical and clinical research settings for its potential comprehensive effects on glucose homeostasis, energy expenditure, and body composition.
Triple Agonist Mechanism Overview
Laboratory research has demonstrated that GLP-1R’s unique triple agonist properties enable simultaneous activation of GIP receptors (GIPR), GLP-1 receptors (GLP-1R), and glucagon receptors (GCGR).2 This multi-receptor engagement has been hypothesized to produce complementary and potentially synergistic effects on metabolic pathways. GIP and GLP-1 receptor activation contributes to enhanced insulin secretion and appetite suppression, while glucagon receptor activation may increase energy expenditure and promote lipolysis, creating a comprehensive metabolic modulation profile.
Research investigations have suggested that the addition of glucagon receptor agonism to dual GIP/GLP-1 agonism may provide additional metabolic benefits, particularly in energy balance and substrate utilization.3 Studies have indicated that glucagon receptor activation may stimulate hepatic glucose output under appropriate conditions while also increasing energy expenditure through thermogenic mechanisms. The balanced integration of these three receptor pathways in GLP-1R has positioned it as an important research tool for investigating complex metabolic regulation.
GLP-1R Chemical Structure
Molecular weight: ~4700 g/mol (approximate)
Form: Lyophilized powder
Purity: >99% (HPLC verified)
Modification: Lipidated triple receptor agonist peptide
Receptor targets: GIP, GLP-1, and Glucagon receptors
Research and Metabolic Studies
Metabolic Regulation Research
Extensive preclinical research has examined GLP-1R’s comprehensive effects on metabolic function. Studies in various animal models have reported that triple receptor activation correlates with substantial improvements in glucose control, insulin sensitivity, and glycemic variability.4 Research data has suggested that the addition of glucagon receptor agonism to incretin-based therapy may enhance metabolic outcomes beyond what is achievable with GLP-1 or dual GIP/GLP-1 agonists alone.
Energy Expenditure and Thermogenesis Studies
Research teams have investigated GLP-1R’s potential influence on energy expenditure and thermogenic pathways. Laboratory studies have suggested that glucagon receptor activation component may stimulate metabolic rate and promote fat oxidation through multiple mechanisms.5 Preclinical investigations have examined the peptide’s effects on brown adipose tissue activation, mitochondrial function, and substrate utilization patterns. These studies have contributed to understanding how multi-receptor agonism might modulate energy balance more comprehensively than single-pathway approaches.
Body Composition Research
Significant research has focused on GLP-1R’s potential effects on body composition parameters. Studies have examined changes in fat mass, lean mass preservation, and regional adipose tissue distribution in experimental models.6 Research data has suggested that the triple agonist mechanism may produce favorable effects on body composition, potentially through combined influences on appetite suppression, energy expenditure enhancement, and metabolic rate modulation. These findings have important implications for understanding integrated metabolic regulation.
Product Specifications
- Size: 30mg per vial
- Contents: GLP-R (GLP-1R) (30mg)
- Form: Lyophilized powder
- Purity: >99% (verified by HPLC and Mass Spectrometry)
- Storage: Store at -20°C protected from light
- Reconstitution: Use bacteriostatic water for laboratory applications
- Stability: Extended stability when stored under recommended conditions
Quality Assurance and Documentation
- Third-party laboratory tested for purity and identity verification
- Certificate of Analysis (COA) available upon request for each batch
- HPLC chromatography results provided
- Mass spectrometry data available
- Manufactured under strict quality control protocols
- Batch-specific documentation and traceability
- Compliance with research-grade standards
Research Applications
- Triple incretin receptor signaling investigations
- GIP, GLP-1, and glucagon receptor interaction studies
- Comprehensive metabolic regulation research
- Energy expenditure and thermogenesis studies
- Body composition modulation research
- Glucose homeostasis mechanism investigations
- Appetite regulation pathway studies
- Hepatic glucose metabolism research
- Adipose tissue function studies
- Multi-receptor agonist pharmacology research
Important Research Notice
FOR LABORATORY AND RESEARCH USE ONLY. This product is intended exclusively for scientific research, in vitro studies, and laboratory investigations. This compound is not intended for human or animal consumption, clinical applications, or any diagnostic or therapeutic uses.
Researchers should consult relevant scientific literature and follow appropriate safety protocols when handling this research compound. Proper laboratory equipment, personal protective equipment, and training are required for working with this material.
Regulatory Compliance Statement
This product is sold as a research chemical for laboratory use only. Shrine Peptides operates as a chemical supplier. Shrine Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Shrine Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
The statements made within this product description have not been evaluated by the US Food and Drug Administration. The products we offer are not intended to diagnose, treat, cure or prevent any disease. Human/Animal Consumption Prohibited. Laboratory/In-Vitro Experimental Use Only.
Please review and adhere to our Terms and Conditions before ordering.
References:
- Coskun, T., Sloop, K. W., Loghin, C., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Diabetes, obesity & metabolism, 20(11), 2642-2653. https://doi.org/10.1111/dom.13426
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple-Hormone-Receptor Agonist GLP-1R for Obesity – A Phase 2 Trial. The New England journal of medicine, 389(6), 514-526. https://doi.org/10.1056/NEJMoa2301972
- Rosenstock, J., Frias, J., Jastreboff, A. M., et al. (2023). GLP-1R, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Nature medicine, 29(8), 2023-2032. https://doi.org/10.1038/s41591-023-02476-z
- Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020). How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends in endocrinology and metabolism, 31(6), 410-421. https://doi.org/10.1016/j.tem.2020.02.006
- Samms, R. J., Christe, M. E., Collins, K. A., et al. (2021). GIPR agonism mediates weight-independent insulin sensitization by GLP-T in obese mice. The Journal of clinical investigation, 131(12), e146353. https://doi.org/10.1172/JCI146353
Reviews
There are no reviews yet.